Showing results (361-370 of 410) with videos related to

Sort By:
Pageof 41
Molecular Therapy. Oncology|December 1, 2025
Oncolytic Newcastle-disease-virus-mediated CD47 blockade in preclinical melanoma and pancreatic cancer modelsJacob G E Yates, Lily Chan, Alyssa E Bogle, et al.
Molecular Therapy. Oncology|December 25, 2024
Employing splice-switching oligonucleotides and AAVrh74.U7 snRNA to target insulin receptor splicing and cancer hallmarks in osteosarcomaSafiya Khurshid, Akila S Venkataramany, Matias Montes, et al.
Molecular Therapy. Oncology|January 15, 2025
Enhancing NK cell-mediated tumor killing of B7-H6+ cells with bispecific antibodies targeting allosteric sites of NKp30Léxane Fournier, Paul Arras, Lukas Pekar, et al.
Molecular Therapy. Oncology|January 6, 2025
Optimized protocol for culturing menstrual blood-derived MSCs for combination with oncolytic adenoviruses in cancer treatmentMarcel Costa-Garcia, Laura Moya-Borrego, Ramon Alemany Bonastre, et al.
Molecular Therapy. Oncology|January 17, 2025
Targeting CD45 by gene-edited CAR T cells for leukemia eradication and hematopoietic stem cell transplantation preconditioningValeria M Stepanova, Dmitry V Volkov, Daria S Osipova, et al.
Molecular Therapy. Oncology|December 6, 2024
Newcastle disease virus harboring the PTEN gene inhibits pancreatic cancer growth by inhibiting PI3K/AKT/mTOR signaling and activating apoptosisSeonhee Kim, Bo-Kyoung Jung, Jinju Kim, et al.
Molecular Therapy. Oncology|September 12, 2024
Identification of novel inhibitors of the transcriptional coactivator MRTF-A for HCC therapyMiriam Jasmin Franz, Pia Wenisch, Petra Wohlleben, et al.
Molecular Therapy. Oncology|September 12, 2024
Senescence-associated secretory phenotype regulation by dual drug delivery biomimetic nanoplatform for enhanced tumor chemotherapyAnni Wang, Shiyi Li, Ru Zhang, et al.
Molecular Therapy. Oncology|September 18, 2024
Lemur tail kinase 3 serves as a predictor of patient outcomes and a target for the treatment of ovarian cancerGhassan M Saed, Nicole M Fletcher, Harvey Sharma, et al.
Molecular Therapy. Oncology|October 2, 2024
The reovirus variant RP116 is oncolytic in immunocompetent models and generates reduced neutralizing antibodies to Type 3 DearingKi-Hoon Song, Xiao Xiang, So Hyun Lee, et al.
Pageof 41